Liposomes act as stronger sub-unit vaccine adjuvants when compared to microspheres

References

• Agger EM, Andersen P. Tuberculosis subunit vaccine development: On the role of interferon-gamma. Vaccine 2001; 19: 2298–2302
   PubMed Web of Science ®Google Scholar
• Ahsan F, Rivas IP, Khan MA, Torres Suarez AI. Targeting to macrophages: Role of physicochemical properties of particulate carriers—liposomes and microspheres—on the phagocytosis by macrophages. J Control Release 2002; 79: 29–40
   PubMed Web of Science ®Google Scholar
• Allison AG, Gregoriadis G. Liposomes as immunological adjuvants. Nature 1974; 252: 252
   PubMed Web of Science ®Google Scholar
• Audran R, Peter K, Dannull J, Men Y, Scandella E, Groettrup M, Gander B, Corradin G. Encapsulation of peptides in biodegradable microspheres prolongs their MHC class-I presentation by dendritic cells and macrophages in vitro. Vaccine 2003; 21: 1250–1255
   PubMed Web of Science ®Google Scholar
• Barreleiro PCA, Olofsson G, Brown W, Edwards K, Bonassi NM, Feitosa E. Interaction of octaethylene glycol n-dodecyl monoether with dioctadecyldimethylammonium bromide and chloride vesicles. Langmuir 2002; 18: 1024–1029
   Web of Science ®Google Scholar
• Behr MA, Small PM. Has BCG attenuated to impotence?. Nature 1997; 389: 133–134
   PubMed Web of Science ®Google Scholar
• Benatti CR, Tiera MJ, Feitosa E, Olofsson G. Phase behavior of synthetic amphiphile vesicles investigated by calorimetry and fluorescence methods. Thermochim Acta 1999; 328: 137–142
   Web of Science ®Google Scholar
• Blandamer MJ, Briggs B, Cullis PM, Irlam KD, Kirby SD, Engberts JBFN. Formation of vesicular bilayers in aqueous solutions containing mixtures of dialkyldimethylammonium bromides. J Mol Liquids 1998; 75: 181–187
   Web of Science ®Google Scholar
• Boury F, Ivanova T, Panaiotov I, Proust JE, Bois A, Richou J. Dynamic properties of poly(dl-lactide) and polyvinyl alcohol monolayers at the air/water and dichloromethane/water interfaces. J Coll Int Sci 1995; 169: 380–392
   Web of Science ®Google Scholar
• Bramwell VW, Perrie Y. Particulate delivery systems for vaccines. Crit Rev Ther Drug Carrier Syst 2005; 22: 151–214
   PubMed Web of Science ®Google Scholar
• Briones M, Singh M, Ugozzoli M, Kazzaz J, Klakamp S, Ott G, O'Hagan D. The preparation, characterization, and evaluation of cationic microparticles for DNA vaccine delivery. Pharm Res 2001; 18: 709–712
   PubMed Web of Science ®Google Scholar
• Carmona-Ribeiro AM, Ortis F, Schumacher RI, Armelin MCS. Interactions between cationic vesicles and cultured mammalian cells. Langmuir 1997; 13: 2215–2218
   Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs—Worldwide, 2000–2004. 2006; 55: 301–305
   Google Scholar
• Chung TH, Wu SH, Yao M, Lu CW, Lin YS, Hung Y, Mou CY, Chen YC, Huang DM. The effect of surface charge on the uptake and biological function of mesoporous silica nanoparticles in 3T3-L1 cells and human mesenchymal stem cells. Biomaterials 2007; 28: 2959–2966
   PubMed Web of Science ®Google Scholar
• Colditz GA, Berkey CS, Mosteller F, Brewer TF, Wilson ME, Burdick E, Fineberg HV. The efficacy of bacillus Calmette–Guerin vaccination of newborns and infants in the prevention of tuberculosis: Meta-analyses of the published literature. Pediatrics 1995; 96: 29–35
   PubMed Web of Science ®Google Scholar
• Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, Gordon SV, Eiglmeier K, Gas S, Barry CE, III, Tekaia F, Badcock K, Basham D, Brown D, Chillingworth T, Connor R, Davies R, Devlin K, Feltwell T, Gentles S, Hamlin N, Holroyd S, Hornsby T, Jagels K, Krogh A, McLean J, Moule S, Murphy L, Oliver K, Osborne J, Quail MA, Rajandream MA, Rogers J, Rutter S, Seeger K, Skelton J, Squares R, Squares S, Sulston JE, Taylor K, Whitehead S, Barrell BG. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998; 393: 537–544
   PubMed Web of Science ®Google Scholar
• Coombes AG, Yeh MK, Lavelle EC, Davis SS. The control of protein release from poly(dl-lactide-co-glycolide) microparticles by variation of the external aqueous phase surfactant in the water-in oil-in water method. J Control Release 1998; 52: 311–320
   PubMed Web of Science ®Google Scholar
• Copland MJ, Rades T, Davies NM. Hydration of lipid films with an aqueous solution of Quil A: A simple method for the preparation of immune-stimulating complexes. Int J Pharm 2000; 196: 135–139
   PubMedGoogle Scholar
• Davidsen J, Rosenkrands I, Christensen D, Vangala A, Kirby D, Perrie Y, Agger EM, Andersen P. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6′-dibehenate)—a novel adjuvant inducing both strong CMI and antibody responses. Biochim Biophys Acta 2005; 1718: 22–31
   PubMed Web of Science ®Google Scholar
• Demana PH, Davies NM, Hook S, Rades T. Quil A-lipid powder formulations releasing ISCOMs and related colloidal structures upon hydration. J Control Release 2005; 103: 45–59
   PubMed Web of Science ®Google Scholar
• Denis-Mize KS, Dupuis M, Singh M, Woo C, Ugozzoli M, O'Hagan DT, Donnelly JJ, III, Ott G, McDonald DM. Mechanisms of increased immunogenicity for DNA-based vaccines adsorbed onto cationic microparticles. Cell Immunol 2003; 225: 12–20
   PubMed Web of Science ®Google Scholar
• Doherty TM, Olsen AW, van PL, Andersen P. Oral vaccination with subunit vaccines protects animals against aerosol infection with Mycobacterium tuberculosis. Infect Immun 2002; 70: 3111–3121
   PubMed Web of Science ®Google Scholar
• Eldridge JH, Staas JK, Meulbroek JA, Tice TR, Gilley RM. Biodegradable and biocompatible poly(dl-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect Immun 1991; 59: 2978–2986
   PubMed Web of Science ®Google Scholar
• Ellner JJ, Hirsch CS, Whalen CC. Correlates of protective immunity to Mycobacterium tuberculosis in humans. Clin Infect Dis 2000; 30(Suppl 3)S279–S282
   PubMedGoogle Scholar
• Esposito E, Sebben S, Cortesi R, Menegatti E, Nastruzzi C. Preparation and characterization of cationic microspheres for gene delivery. Int J Pharm 1999; 189: 29–41
   PubMed Web of Science ®Google Scholar
• Feitosa E, Barreleiro PCA, Olofsson G. Phase transition in dioctadecyldimethylammonium bromide and chloride vesicles prepared by different methods. Chem Phys Lipids 2000; 105: 201–213
   PubMed Web of Science ®Google Scholar
• Fine PE. Variation in protection by BCG: Implications of and for heterologous immunity. Lancet 1995; 346: 1339–1345
   PubMed Web of Science ®Google Scholar
• Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 1993; 178: 2249–2254
   PubMed Web of Science ®Google Scholar
• Gregoriadis G. Immunological adjuvants: A role for liposomes. Immunol Today 1990; 11: 89–97
   PubMedGoogle Scholar
• Gregoriadis G, Allison AC. Entrapment of proteins in liposomes prevents allergic reactions in pre-immunised mice. FEBS Lett 1974; 45: 71–74
   PubMed Web of Science ®Google Scholar
• Gregoriadis G, McCormack B, Obrenovic M, Saffie R, Zadi B, Perrie Y. Vaccine entrapment in liposomes. Methods 1999; 19: 156–162
   PubMed Web of Science ®Google Scholar
• Gupta RK, Varanelli CL, Griffin P, Wallach DF, Siber GR. Adjuvant properties of non-phospholipid liposomes (Novasomes) in experimental animals for human vaccine antigens. Vaccine 1996; 14: 219–225
   PubMed Web of Science ®Google Scholar
• Heath TD, Lopez NG, Papahadjopoulos D. The effects of liposome size and surface charge on liposome-mediated delivery of methotrexate-[gamma]-aspartate to cells in vitro. Biochim Biophys Acta 1985; 820: 74–84
   PubMed Web of Science ®Google Scholar
• Holten-Andersen L, Doherty TM, Korsholm KS, Andersen P. Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines. Infect Immun 2004; 72: 1608–1617
   PubMed Web of Science ®Google Scholar
• Huang M, Khor E, Lim LY. Uptake and cytotoxicity of chitosan molecules and nanoparticles: Effects of molecular weight and degree of deacetylation. Pharm Res 2004; 21: 344–353
   PubMed Web of Science ®Google Scholar
• Huang M, Fong CW, Khor E, Lim LY. Transfection efficiency of chitosan vectors: Effect of polymer molecular weight and degree of deacetylation. J Control Release 2005; 106: 391–406
   PubMed Web of Science ®Google Scholar
• Jiang W, Gupta RK, Deshpande MC, Schwendeman SP. Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv Drug Deliv Rev 2005; 57: 391–410
   PubMed Web of Science ®Google Scholar
• Jilek S, Merkle HP, Walter E. DNA-loaded biodegradable microparticles as vaccine delivery systems and their interaction with dendritic cells. Adv Drug Deliv Rev 2005; 57: 377–390
   PubMed Web of Science ®Google Scholar
• Kersten GFA, Crommelin DJA. Liposomes and ISCOMS as vaccine formulations. Biochim Biophys Acta 1995; 1241: 117
   PubMed Web of Science ®Google Scholar
• Kirby DJ, Rosenkrands I, Agger EM, Andersen P, Coombes AGA, Perrie Y. PLGA microspheres for the delivery of a novel subunit TB vaccine. J Drug Target 2008; 16: 282–293
   PubMed Web of Science ®Google Scholar
• Langer R, Folkman J. Polymers for the sustained release of proteins and other macromolecules. Nature 1976; 263: 797–800
   PubMed Web of Science ®Google Scholar
• Lendemans DG, Myschik J, Hook S, Rades T. Cationic cage-like complexes formed by DC-cholesterol, Quil-A, and phospholipid. J Pharm Sci 2005; 94: 1794–1807
   PubMed Web of Science ®Google Scholar
• Liu MA. Vaccines timeline. Interview by Philip Cohen. BMJ 1999; 319: 1301
   PubMedGoogle Scholar
• Manesis EK, Cameron CH, Gregoriadis G. Incorporation of hepatitis-B surface antigen (HBsAg) into liposomes. Biochem Soc Trans 1978; 6: 925–928
   PubMedGoogle Scholar
• McMurray DN. Recent progress in the development and testing of vaccines against human tuberculosis. Int J Parasitol 2003; 33: 547–554
   PubMed Web of Science ®Google Scholar
• Mohammed AR, Weston N, Coombes AG, Fitzgerald M, Perrie Y. Liposome formulation of poorly water soluble drugs: Optimisation of drug loading and ESEM analysis of stability. Int J Pharm 2004; 285: 23–34
   PubMed Web of Science ®Google Scholar
• Mollenkopf HJ, Dietrich G, Fensterle J, Grode L, Diehl KD, Knapp B, Singh M, O'Hagan DT, Ulmer JB, Kaufmann SH. Enhanced protective efficacy of a tuberculosis DNA vaccine by adsorption onto cationic PLG microparticles. Vaccine 2004; 22: 2690–2695
   PubMed Web of Science ®Google Scholar
• Mora M, Veggi D, Santini L, Pizza M, Rappuoli R. Reverse vaccinology. Drug Discov Today 2003; 8: 459–464
   PubMed Web of Science ®Google Scholar
• Myschik J, Lendemans DG, McBurney WT, Demana PH, Hook S, Rades T. On the preparation, microscopic investigation and application of ISCOMs. Micron 2006; 37: 724–734
   PubMed Web of Science ®Google Scholar
• O'Hagan DT, Rahman D, McGee JP, Jeffery H, Davies MC, Williams P, Davis SS, Challacombe SJ. Biodegradable microparticles as controlled release antigen delivery systems. Immunology 1991; 73: 239–242
   PubMed Web of Science ®Google Scholar
• O'Hagan DT, MacKichan ML, Singh M. Recent developments in adjuvants for vaccines against infectious diseases. Biomol Eng 2001; 18: 69–85
   PubMedGoogle Scholar
• Ogawa Y, Yamamoto M, Okada H, Yashiki T, Shimamoto T. A new technique to efficiently entrap leuprolide acetate into microcapsules of polylactic acid or copoly(lactic/glycolic) acid. Chem Pharm Bull (Tokyo) 1988; 36: 1095–1103
   PubMed Web of Science ®Google Scholar
• Olsen AW, van Pinxteren LAH, Okkels LM, Rasmussen PB, Andersen P. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Infect Immun 2001; 69: 2773–2778
   PubMed Web of Science ®Google Scholar
• Perrie Y, Frederik PM, Gregoriadis G. Liposome-mediated DNA vaccination: The effect of vesicle composition. Vaccine 2001; 19: 3301–3310
   PubMed Web of Science ®Google Scholar
• Perrie Y, Obrenovic M, McCarthy D, Gregoriadis G. Liposome (lipodine)—mediated DNA vaccination by the oral route. J Liposome Res 2002; 12: 185–197
   PubMed Web of Science ®Google Scholar
• Perrie Y, McNeil S, Vangala A. Liposome-mediated DNA immunisation via the subcutaneous route. J Drug Target 2003; 11: 555–563
   PubMed Web of Science ®Google Scholar
• Perrie Y, Kirby D, Bramwell VW, Mohammed AR. Recent developments in particulate-based vaccines. Recent Patents on Drug Delivery and Formulation 2007a; 1: 117–130
   PubMedGoogle Scholar
• Perrie Y, Mohammed AU, Vangala A, McNeil SE. Environmental scanning electron microscopy offers real-time morphological analysis of liposomes and niosomes. J Liposome Res 2007b; 17: 27–37
   PubMed Web of Science ®Google Scholar
• Peyre M, Fleck R, Hockley D, Gander B, Sesardic D. In vivo uptake of an experimental microencapsulated diphtheria vaccine following sub-cutaneous immunisation. Vaccine 2004; 22: 2430–2437
   PubMed Web of Science ®Google Scholar
• Preis I, Langer RS. A single-step immunization by sustained antigen release. J Immunol Methods 1979; 28: 193–197
   PubMed Web of Science ®Google Scholar
• Ravi Kumar MNV, Bakowsky U, Lehr CM. Preparation and characterization of cationic PLGA nanospheres as DNA carriers. Biomaterials 2004; 25: 1771–1777
   PubMed Web of Science ®Google Scholar
• Singh AK, Kasinath BS, Lewis EJ. Interaction of polycations with cell-surface negative charges of epithelial cells. Biochim Biophys Acta 1992; 1120: 337–342
   PubMed Web of Science ®Google Scholar
• Singh M, Briones M, Ott G, O'Hagan D. Cationic microparticles: A potent delivery system for DNA vaccines. Proc Natl Acad Sci U S A 2000; 97: 811–816
   PubMed Web of Science ®Google Scholar
• Smith Korsholm K, Agger EM, Foged C, Christensen D, Dietrich J, Andersen CS, Geisler C, Andersen P. The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes. Immunology 2007; 121: 216–226
   PubMed Web of Science ®Google Scholar
• Storni T, Kundig TM, Senti G, Johansen P. Immunity in response to particulate antigen-delivery systems. Adv Drug Deliv Rev 2005; 57: 333–355
   PubMed Web of Science ®Google Scholar
• Strong P, Clark H, Reid K. Intranasal application of chitin microparticles down-regulates symptoms of allergic hypersensitivity to Dermatophagoides pteronyssinus and Aspergillus fumigatus in murine models of allergy. Clin Exp Allergy 2002; 32: 1794–1800
   PubMed Web of Science ®Google Scholar
• Tabata Y, Ikada Y. Effect of the size and surface charge of polymer microspheres on their phagocytosis by macrophage. Biomaterials 1988a; 9: 356–362
   PubMed Web of Science ®Google Scholar
• Tabata Y, Ikada Y. Macrophage phagocytosis of biodegradable microspheres composed of l-lactic acid/glycolic acid homo- and copolymers. J Biomed Mater Res 1988b; 22: 837–858
   PubMed Web of Science ®Google Scholar
• Thiele L, Diederichs JE, Reszka R, Merkle HP, Walter E. Competitive adsorption of serum proteins at microparticles affects phagocytosis by dendritic cells. Biomaterials 2003a; 24: 1409–1418
   PubMed Web of Science ®Google Scholar
• Thiele L, Diederichs JE, Reszka R, Merkle HP, Walter E. Competitive adsorption of serum proteins at microparticles affects phagocytosis by dendritic cells. Biomaterials 2003b; 24: 1409–1418
   PubMed Web of Science ®Google Scholar
• Vangala A, Kirby D, Rosenkrands I, Agger EM, Andersen P, Perrie Y. A comparative study of cationic liposome and niosome-based adjuvant systems for protein subunit vaccines: Characterisation, environmental scanning electron microscopy and immunisation studies in mice. J Pharm Pharmacol 2006; 58: 787–799
   PubMed Web of Science ®Google Scholar
• Vangala A, Bramwell VW, McNeil S, Christensen D, Agger EM, Perrie Y. Comparison of vesicle based antigen delivery systems for delivery of hepatitis B surface antigen. J Control Release 2007; 119: 102–110
   PubMed Web of Science ®Google Scholar
• Wischke C, Borchert HH, Zimmermann J, Siebenbrodt I, Lorenzen DR. Stable cationic microparticles for enhanced model antigen delivery to dendritic cells. J Control Release 2006; 114: 359–368
   PubMed Web of Science ®Google Scholar
• World Health Organisation. 1997. Anti-tuberculosis drug resistance in the world. Geneva, Switzerland, World Health Organisation, The WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance 1994–1997.
   Google Scholar
• World Health Organisation. 2001. Global tuberculosis control, Geneva, Switzerland, World Health Organisation. WHO Report.
   Google Scholar
• World Health Organisation. 2002. The global plan to stop tuberculosis, Geneva, Switzerland, World Health Organisation. WHO Report.
   Google Scholar
• World Health Organisation. 2006a. The Global Plan to Stop TB 2006–2015, Geneva, Switzerland, World Health Organisation. STOP TB Partnership.
   Google Scholar
• World Health Organisation. 2006b. Tuberculosis, Geneva, Switzerland, World Health Organisation. Fact sheet No. 104.
   Google Scholar
• World Health Organisation. 2007. TB: Anywhere is Everywhere, Geneva, Switzerland, World Health Organisation. World TB Day 2007: WHO Factsheet.
   Google Scholar